Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aluminium Chloride→

Aluminium Chloride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7446-70-0
Molecular formula
AlCl3
Molecular weight
133.34 g/mol
Drug class
Topical antiperspirant and astringentinorganic aluminium salt
Mechanism of action
Aluminium chloride reacts with components of sweat and proteins within the eccrine sweat duct, producing temporary ductal obstruction and reducing sweat reaching the skin surface. This is a local physical/chemical effect rather than systemic pharmacology.
Indications / reported uses
  • Topical treatment of primary focal hyperhidrosis, particularly axillary, palmar and plantar excessive sweating, using the product-specific concentration and application schedule

Sources: NHS — Hyperhidrosis treatment · British Association of Dermatologists — Hyperhidrosis patient information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aluminium Chloride Environmental Risk Assessment (ERA) (the Aluminium Chloride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.